Black Diamond Therapeutics Inc. (NASDAQ:BDTX) is one of the best biotech penny stocks to buy according to analysts. On ...
The top content from the World Conference on Lung Cancer (WCLC) 2025 highlighted panels and abstracts presented during the ...
The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations. Patients with non–small cell lung cancer (NSCLC) who have uncommon EGFR mutations appear to have ...
To guide clinical care for patients with MPLCs, it’s important to identify the possibility of discordant EGFR status in individual tumors. EGFR mutations occur independently in patients with ...
According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer. Certain features may make patients ...
The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...
Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized ...
In a recent study published in The Lancet Regional Health-Southeast Asia, researchers developed an artificial intelligence (AI)-based predictive system (AIPS) model for the early detection of lung ...
Treatment modalities and survival outcomes in patients with hepatocellular carcinoma with brain metastases (HCC-BM): A large national study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback